The EuroFlow™ strategy to monitor minimal residual disease (MRD) by Next Generation Flow has been focused in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients.
The BCP-ALL MRD kit, designed following the fully-standardized EuroFlow™ 8-color antibody panel, allows measuring MRD and discriminating between normal and malignant BCP cells in 99% of studied BCP-ALL patients.
Protected by patent.
Pacific Blue™ is a trademark of Life Technologies Corporation
This product should be used in combination with the EuroFlow™ Standard Operation Procedures for instrument setup:
- The protocol for BD FACSCanto™ II “EuroFlow SOP for Instrument set-up and compensation Version 1.2.1 – 29 October 2019” can be downloaded here.
- The protocol for BD FACSLyric™ “EuroFlow SOP for instrument set-up and compensation for BD Lyric instrument for the 8-color panels Version 1.8 – 1 July 2019” can be downloaded here.